Aflibercept for Wet Age-Related Macular Degeneration
How Aflibercept Treats Wet AMD
Wet age-related macular degeneration develops when abnormal blood vessels called choroidal neovascularization grow beneath your macula and leak fluid and blood into the retinal layers. This leaking causes swelling that damages the photoreceptor cells you depend on for central vision. Without treatment, the fluid buildup can lead to scarring and permanent vision loss. Aflibercept targets the proteins that drive this abnormal vessel growth.
According to the AAO, aflibercept acts as a soluble decoy receptor that binds both VEGF-A (vascular endothelial growth factor A) and placental growth factor (PlGF), blocking their ability to activate receptors that trigger abnormal blood vessel growth and leaking. By trapping these proteins, aflibercept reduces fluid leakage and swelling beneath your retina. The FDA approved aflibercept (2 mg) for wet AMD in November 2011.
In the VIEW 1 and VIEW 2 phase 3 trials, aflibercept dosed every eight weeks after a three-month loading phase was noninferior to ranibizumab given monthly in maintaining or improving vision at 52 weeks, according to published data (NCBI Bookshelf, 2014). Patients on aflibercept averaged 11.2 injections over two years compared to 16.5 with monthly ranibizumab, meaning fewer total injections for similar visual outcomes.
Your retina specialist may recommend aflibercept if you have wet AMD and need effective VEGF suppression with the possibility of bimonthly dosing after the loading phase. Aflibercept is one of the most prescribed anti-VEGF medications worldwide. Your doctor selects it based on your disease characteristics, treatment history, insurance coverage, and dosing preference. Aflibercept works well as both a first-line treatment and as a switch option for patients who have tried other anti-VEGF medications.
What Treatment Involves
Your retina specialist delivers aflibercept as an intravitreal injection. Your doctor applies numbing drops and antiseptic solution to your eye before the procedure. A small-gauge needle passes through the white part of your eye to deliver the medication into the vitreous cavity. The injection takes seconds. Most patients feel pressure but not sharp pain. Your vision may be blurry for a few hours afterward, so bring a driver to your appointment. You can resume most normal activities the next day.
Standard aflibercept (2 mg) starts with one injection every four weeks for three months (the loading phase), then one injection every eight weeks thereafter, according to published dosing guidance. Your retina specialist monitors your OCT imaging at each visit and may adjust the interval using a treat-and-extend approach, extending beyond eight weeks for patients whose retina stays dry.
According to Regeneron (2023), the FDA approved high-dose aflibercept (8 mg) in August 2023. The PULSAR trial showed that 8 mg dosing at 12- to 16-week intervals was noninferior to standard 2 mg dosing every eight weeks. According to Regeneron (2024), 71 percent of patients achieved 16-week intervals or longer at 96 weeks. In April 2026, the FDA expanded approved dosing intervals for high-dose aflibercept up to every 30 weeks, the widest dosing range of any injectable anti-VEGF.
According to Ophthalmology Times (2023), two aflibercept biosimilars received FDA approval in 2023. Biosimilars are biologic medications that researchers have tested and confirmed to match the original drug in safety, efficacy, and quality. They offer the same clinical benefit at a lower cost. Your retina specialist may discuss biosimilar options if they are available at your treatment center and covered by your insurance plan. Biosimilars expand access to aflibercept treatment for patients whose insurance favors lower-cost options.
Safety and Side Effects
According to safety information from the manufacturer, the most common side effects include conjunctival hemorrhage (bleeding on the white of the eye), eye pain, cataract, vitreous detachment, vitreous floaters, and increased eye pressure. These effects are mild and resolve without treatment within a few days. Your doctor checks your eye pressure within 60 minutes after injection to ensure it returns to a safe range before you leave the office.
Endophthalmitis (infection inside the eye) and retinal detachment occur in fewer than 0.1 percent of injections, according to safety data. Your retina specialist uses sterile technique to minimize these risks. The risk remains low regardless of how many injections you have received over the course of your treatment.
Call your retina specialist right away if you develop increased eye pain, worsening redness, sensitivity to light, or vision changes after an injection. These symptoms can indicate endophthalmitis or other complications that require urgent treatment. Do not wait to see if symptoms resolve on their own. Your retina specialist has protocols to evaluate and manage these rare events without delay.
Questions About Aflibercept Treatment
Standard aflibercept delivers 2 mg per injection and is given every eight weeks after loading. High-dose aflibercept delivers 8 mg in the same small injection volume, providing a larger reservoir of medication that lasts longer. The primary benefit of the high dose is fewer injections per year, not superior vision outcomes. Your retina specialist can discuss which formulation fits your treatment plan.
Your retina specialist can switch you from ranibizumab, bevacizumab, faricimab, or another anti-VEGF medication to aflibercept. Doctors may recommend switching if your current drug requires more frequent injections than aflibercept or if your disease activity suggests a different mechanism could help. Your doctor monitors your response after any medication change.
Wet AMD is a chronic condition, and treatment is ongoing. Most patients need aflibercept injections for years. Your retina specialist works to extend your injection interval as far as possible while keeping your retina dry. A small number of patients may pause treatment under close monitoring, but your doctor makes this decision with imaging guidance.
Yes. FDA-approved biosimilars must demonstrate the same clinical efficacy, safety, and quality as the original medication through rigorous testing. Your retina specialist would not prescribe a biosimilar unless it met the same standard of care. Biosimilars may reduce your out-of-pocket costs depending on your insurance coverage.
Your vision may be blurry for several hours after the injection, so bring a driver to your appointment. You can resume driving the next day once your vision clears. If your doctor dilated your pupils for other exam components, the blurriness from dilation may last four to six hours.
Manufacturer patient assistance programs, biosimilar options, and bevacizumab (a lower-cost off-label alternative) are all available. Talk to your retina specialist and their billing team about your financial situation. Most practices work with patients to find a treatment option that fits their budget while maintaining effective care. Financial barriers should never prevent you from receiving the anti-VEGF treatment your eyes need.
Stay Consistent With Your Aflibercept Treatment
Aflibercept protects your central vision by controlling the abnormal blood vessels beneath your retina. Attend all scheduled injection and monitoring appointments, and talk to your retina specialist about any concerns with your treatment plan.